ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027

MARKET OUTLOOK
A Triton Market Research report states that the Asia-Pacific liquid biopsy market is expected to grow in terms of revenue with a CAGR of 23.04% during the forecast period 2019 to 2027.
India, China, Japan, South Korea, ASEAN countries, Australia & New Zealand and countries in rest of APAC together form the market for liquid biopsy in the Asia-Pacific region.
Many providers of diagnostic biopsy testing solutions will want to step into developing countries in order to leverage on the untapped diagnostic testing market in the coming years. Generally, patients in rural areas postpone diagnosis and treatment of various unmet chronic diseases including cancer, kidney, and liver diseases due to difficulty in accessing transport, lack of accessible healthcare facilities, and marginally lower income compared to urban areas. Over the estimated period, enhanced diagnostics tools, better treatment monitoring, faster response times, increase in availability of OTC tests, easy availability of biopsy solutions at a cheaper price, and high amount of research grants & funding projects will establish a number of diagnostic centers around the world, especially in rural areas of developing countries. These factors will provide a vast market opportunity for biopsy solution providers.
COMPETITIVE OUTLOOK
The key companies profiled in the report on the liquid biopsy market include Cintec Medical Ltd., Roche Diagnostics Corporation, Ad-Tech Medical Instrument Corp., I.M.S. Internazionale Medico Scientifica Srl, QIAGEN N.V., Becton, Dickinson, Planmeca Oy and Bio-Rad Laboratories, Inc.

TABLE OF CONTENT
1. ASIA-PACIFIC LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1. CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2. DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3. TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4. RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1. HIGH COST OF TEST
2.9.2. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10. MARKET OPPORTUNITIES
2.10.1. ADVANCEMENT IN TECHNOLOGY
2.10.2. RISING NUMBER OF CANCER PATIENTS
2.11. MARKET CHALLENGES
2.11.1. LACK OF REIMBURSEMENT
2.11.2. SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3. LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4. LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6. LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8. LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPES
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9. LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1. ASIA-PACIFIC
10.1.1. MARKET BY THERAPEUTIC APPLICATION
10.1.2. MARKET BY CLINICAL APPLICATION
10.1.3. MARKET BY BIOMARKER TYPE
10.1.4. MARKET BY ANALYSIS PLATFORM
10.1.5. MARKET BY ANALYSIS PURPOSE
10.1.6. MARKET BY PRODUCT
10.1.7. MARKET BY END-USER
10.1.8. COUNTRY ANALYSIS
10.1.8.1. JAPAN
10.1.8.2. CHINA
10.1.8.3. INDIA
10.1.8.4. SOUTH KOREA
10.1.8.5. ASEAN COUNTRIES
10.1.8.6. AUSTRALIA & NEW ZEALAND
10.1.8.7. REST OF APAC
11. COMPETITIVE LANDSCAPE
11.1. AGILENT TECHNOLOGIES, INC.
11.2. BOSTON SCIENTIFIC CORPORATION
11.3. ARGON MEDICAL DEVICES, INC.
11.4. B. BRAUN MELSUNGEN AG
11.5. CINTEC MEDICAL LTD.
11.6. ROCHE DIAGNOSTICS CORPORATION
11.7. AD-TECH MEDICAL INSTRUMENT CORP.
11.8. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9. QIAGEN N.V.
11.10. BECTON, DICKINSON
11.11. PLANMECA OY
11.12. BIO-RAD LABORATORIES, INC.
11.13. CARDINAL HEALTH, INC.
11.14. COOK MEDICAL, INC.
11.15. FISCHER MEDICAL TECHNOLOGIES LLC
11.16. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1. RESEARCH SCOPE & DELIVERABLES
12.1.1. OBJECTIVES OF STUDY
12.1.2. SCOPE OF STUDY
12.2. SOURCES OF DATA
12.2.1. PRIMARY DATA SOURCES
12.2.2. SECONDARY DATA SOURCES
12.3. RESEARCH METHODOLOGY
12.3.1. EVALUATION OF PROPOSED MARKET
12.3.2. IDENTIFICATION OF DATA SOURCES
12.3.3. ASSESSMENT OF MARKET DETERMINANTS
12.3.4. DATA COLLECTION
12.3.5. DATA VALIDATION & ANALYSIS

LIST OF TABLES
TABLE 1 ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
TABLE 3 ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 ASIA-PACIFIC LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 ASIA-PACIFIC LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 ASIA-PACIFIC LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR INDUSTRIES
TABLE 10 ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPES 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 ASIA-PACIFIC LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST CANCER
FIGURE 5 ASIA-PACIFIC LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 ASIA-PACIFIC LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 ASIA-PACIFIC LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 ASIA-PACIFIC LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 ASIA-PACIFIC LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 ASIA-PACIFIC LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 ASIA-PACIFIC LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 ASIA-PACIFIC LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 ASIA-PACIFIC LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PHYSICIANS'OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 ASIA-PACIFIC LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 ASIA-PACIFIC LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 ASIA-PACIFIC LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 ASIA-PACIFIC LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 ASIA-PACIFIC LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 ASIA-PACIFIC LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 ASIA-PACIFIC LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 JAPAN LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 CHINA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 INDIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 37 SOUTH KOREA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 38 AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 39 ASEAN COUNTRIES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 40 REST OF APAC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)